Osiris Therapeutics, Inc. (OSIR) Names Lode Debrabandere Chief Operating Officer

Osiris Therapeutics, Inc. (OSIR) Names Lode Debrabandere Chief Operating Officer

10/23/2012 9:16:55 AM

COLUMBIA, Md.----Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today it has promoted Lode Debrabandere, Ph.D. to the role of Chief Operating Officer (COO) reporting directly to Chief Executive Officer, C. Randal Mills, Ph.D. Dr. Debrabandere has been with Osiris since 2006 in various leadership positions, most recently serving as Senior Vice President for Therapeutics. During his time at Osiris, Dr. Debrabandere has played a key role in the development and approval of Osiris' products including Prochymal® (remestemcel-L), which earlier this year became the world's first stem cell drug to be granted marketing approval by an internationally recognized regulatory authority.

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.